Effectiveness and Safety of Poly (ADP-ribose) Polymerase Inhibitors in Cancer Therapy: A Systematic Review and Meta-analysis

Bao, Zhengqiang; Cao, Chao; Tian, Bo; Chen, Zhihua; Li, Wen; Shen, Huahao; Ying, Songmin

doi:10.1016/j.chest.2016.02.325

Cited by 2 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…178 In a phase II trial assessing the efficacy and safety of olaparib, an oral PARP, the tumor response rate for patients with metastatic pancreatic cancer and a germline BRCA1/2 mutation (n=23) was 21.7% (95% CI, 7.5-43.7). 179 Data from the phase II RUCAPANC trial including 19 patients with a BRCA1/2 mutation and relapsed disease showed an objective response rate of 11% in patients who were administered the PARP inhibitor rucaparib.…”

Section: Targeted Therapiesmentioning

confidence: 99%

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Tempero

Malafa

Al-Hawary

et al. 2017

J Natl Compr Canc Netw

938

897

View full text Add to dashboard Cite

OverviewPancreatic cancer is one of the most common causes of cancer-related death among men and women in the United States. Abstract Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection. J Natl Compr Canc Netw 2017;15(8):1028-1061 doi: 10.6004/jnccn.2017 NCCN Categories of Evidence and Consensus Please NoteThe These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

show abstract

Section: Targeted Therapiesmentioning

confidence: 99%